<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01405794</url>
  </required_header>
  <id_info>
    <org_study_id>50310</org_study_id>
    <nct_id>NCT01405794</nct_id>
  </id_info>
  <brief_title>In-Vivo Assessment of Silver Biomaterial Nano-Toxicity 32 Ppm</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose to study oral commercial silver nanoparticle products on human
      enzyme activity.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change Sodium Blood Levels</measure>
    <time_frame>14 Days</time_frame>
    <description>Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change Potassium Blood Levels</measure>
    <time_frame>14 days</time_frame>
    <description>Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Chloride Blood Levels</measure>
    <time_frame>14 days</time_frame>
    <description>Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Carbon Dioxide Blood Levels</measure>
    <time_frame>14 days</time_frame>
    <description>Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change In Urea Nitrogen Blood Levels</measure>
    <time_frame>14 days</time_frame>
    <description>Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change In Creatinine Blood Levels</measure>
    <time_frame>14 Days</time_frame>
    <description>Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change In Glucose Blood Levels</measure>
    <time_frame>14 Days</time_frame>
    <description>Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change In Alkaline Phosphatase Blood Level</measure>
    <time_frame>14 Days</time_frame>
    <description>Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change In Aspartate Aminotransferase Blood Level</measure>
    <time_frame>14 Days</time_frame>
    <description>Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change In Alanine Aminotransferase Blood Level</measure>
    <time_frame>14 Days</time_frame>
    <description>Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Total Protein Blood Levels</measure>
    <time_frame>14 Days</time_frame>
    <description>Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change In Total Bilirubin Blood Levels</measure>
    <time_frame>14 Days</time_frame>
    <description>Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change In Albumin Blood Levels</measure>
    <time_frame>14 Days</time_frame>
    <description>Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change In Calcium Blood Level</measure>
    <time_frame>14 Days</time_frame>
    <description>Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change In White Blood Count Blood Levels</measure>
    <time_frame>14 Days</time_frame>
    <description>Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change In Red Blood Count Blood Levels</measure>
    <time_frame>14 Days</time_frame>
    <description>Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change In Hemoglobin Blood Levels</measure>
    <time_frame>14 Days</time_frame>
    <description>Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change In Hematocrit Blood Levels</measure>
    <time_frame>14 Days</time_frame>
    <description>Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change In Mean Corpuscular Volume Blood Levels</measure>
    <time_frame>14 Days</time_frame>
    <description>Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change In Mean Corpuscular Hemoglobin Concentration Blood Levels</measure>
    <time_frame>14 Days</time_frame>
    <description>Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change In Platelet Blood Levels</measure>
    <time_frame>14 Days</time_frame>
    <description>Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change In Granulocytes Blood Levels</measure>
    <time_frame>14 Days</time_frame>
    <description>Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change In Lymphocytes Blood Levels</measure>
    <time_frame>14 Days</time_frame>
    <description>Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change In Monocytes Blood Levels</measure>
    <time_frame>14 Days</time_frame>
    <description>Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change In Basophils Blood Levels</measure>
    <time_frame>14 Days</time_frame>
    <description>Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change In Eosinophils Blood Levels</measure>
    <time_frame>14 Days</time_frame>
    <description>Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cytochrome P450 Assay on Dextromethorphan in Participants</measure>
    <time_frame>14 Days</time_frame>
    <description>Assessment Placebo (14 Days) and 32ppm Oral Silver (14 Days). Cytochrome P450 assay is used to determine the function of how Dextromethorphan metabolized. The value represents the peak absorption of the 450 enzyme when dextromethorphan is given during the Silver or Placebo Arm.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cytochrome P450 Assay on Losartan in Participants</measure>
    <time_frame>14 Days</time_frame>
    <description>Assessment Placebo (14 Days) and 32ppm Oral Silver (14 Days). Cytochrome P450 assay is used to determine the function of how Dextromethorphan metabolized. The value represents the peak absorption of the 450 enzyme when dextromethorphan is given during the Silver or Placebo Arm.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cytochrome P450 Assay on Caffeine in Participants</measure>
    <time_frame>14 Days</time_frame>
    <description>Assessment Placebo (14 Days) and 32ppm Oral Silver (14 Days). Cytochrome P450 assay is used to determine the function of how Dextromethorphan metabolized. The value represents the peak absorption of the 450 enzyme when dextromethorphan is given during the Silver or Placebo Arm.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cytochrome P450 Assay on Omeprazole in Participants</measure>
    <time_frame>14 Days</time_frame>
    <description>Assessment Placebo (14 Days) and 32ppm Oral Silver (14 Days). Cytochrome P450 assay is used to determine the function of how Dextromethorphan metabolized. The value represents the peak absorption of the 450 enzyme when dextromethorphan is given during the Silver or Placebo Arm.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cytochrome P450 Assay on Midazolam in Participants</measure>
    <time_frame>14 Days</time_frame>
    <description>Assessment Placebo (14 Days) and 32ppm Oral Silver (14 Days). Cytochrome P450 assay is used to determine the function of how Dextromethorphan metabolized. The value represents the peak absorption of the 450 enzyme when dextromethorphan is given during the Silver or Placebo Arm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cytochrome P450 Assay on Chlorozoxazone in Participants Dosed With Silver</measure>
    <time_frame>14 Days</time_frame>
    <description>Assessment Placebo (14 Days) and 32ppm Oral Silver (14 Days). Cytochrome P450 assay is used to determine the function of how Dextromethorphan metabolized. The value represents the peak absorption of the 450 enzyme when dextromethorphan is given during the Silver or Placebo Arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Change in Systolic Blood Pressure Silver Participants</measure>
    <time_frame>Baseline and 14 Days</time_frame>
    <description>Assessment only completed on the 32ppm Oral Silver part of the trail</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Change in Diastolic Blood Pressure Silver Participants</measure>
    <time_frame>Baseline and 14 Days</time_frame>
    <description>Assessment only completed on the 32ppm Oral Silver part of the trail</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Change in Heart Rate in Silver Participants</measure>
    <time_frame>Baseline and 14 Days</time_frame>
    <description>Assessment only completed on the 32ppm Oral Silver part of the trail</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>32ppm Oral Silver</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>14 Days Active Silver Solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sterile Water</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>No Silver Nanoparticles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>32ppm Silver Particle</intervention_name>
    <description>Oral silver dose of 32ppm</description>
    <arm_group_label>32ppm Oral Silver</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sterile Water No Silver</description>
    <arm_group_label>Sterile Water</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-80 years old without debilitating chronic disease or history of cardiovascular
             event.

        Exclusion Criteria:

          -  Women physically capable of becoming pregnant, who are not using 2 barrier methods of
             birth control;

          -  Any female who is nursing;

          -  History of heavy metal allergy;

          -  History of asthma or Chronic Obstructive Pulmonary Disease;

          -  History of renal impairment;

          -  Symptoms of active upper respiratory disease at time of consent;

          -  Smoking more than 5 cigarettes or equivalent and not able to stop for 48 hours;

          -  Ability to discontinue chronic medications or nutraceuticals for 20 days or 5
             half-lives of the agent, whichever is longer.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Munger, Pharm.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112-5820</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 19, 2011</study_first_submitted>
  <study_first_submitted_qc>July 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2011</study_first_posted>
  <results_first_submitted>July 12, 2013</results_first_submitted>
  <results_first_submitted_qc>September 24, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 26, 2015</results_first_posted>
  <last_update_submitted>May 25, 2016</last_update_submitted>
  <last_update_submitted_qc>May 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Utah</investigator_affiliation>
    <investigator_full_name>mark munger</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>All Study Participants</title>
          <description>All participants were dosed with the placebo (14 days), then they all had a 72hr washout period. Last all participants were dosed with the 32ppm Oral Silver for (14 days).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Dose Placebo (14 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>72 hr Washout</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Dose 32ppm Oral Silver (14 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Participants</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.8" lower_limit="20" upper_limit="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change Sodium Blood Levels</title>
        <description>Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)</description>
        <time_frame>14 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>32ppm Oral Silver</title>
          </group>
        </group_list>
        <measure>
          <title>Change Sodium Blood Levels</title>
          <description>Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141.8" spread="1.6"/>
                    <measurement group_id="O2" value="141.2" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change Potassium Blood Levels</title>
        <description>Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)</description>
        <time_frame>14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>32ppm Oral Silver</title>
          </group>
        </group_list>
        <measure>
          <title>Change Potassium Blood Levels</title>
          <description>Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" spread="0.4"/>
                    <measurement group_id="O2" value="4.4" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Chloride Blood Levels</title>
        <description>Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)</description>
        <time_frame>14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>32ppm Oral Silver</title>
          </group>
        </group_list>
        <measure>
          <title>Change in Chloride Blood Levels</title>
          <description>Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105.0" spread="2.4"/>
                    <measurement group_id="O2" value="105.5" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Carbon Dioxide Blood Levels</title>
        <description>Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)</description>
        <time_frame>14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>32ppm Oral Silver</title>
          </group>
        </group_list>
        <measure>
          <title>Change in Carbon Dioxide Blood Levels</title>
          <description>Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.5" spread="2.3"/>
                    <measurement group_id="O2" value="26.8" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change In Urea Nitrogen Blood Levels</title>
        <description>Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)</description>
        <time_frame>14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>32ppm Oral Silver</title>
          </group>
        </group_list>
        <measure>
          <title>Change In Urea Nitrogen Blood Levels</title>
          <description>Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.9" spread="4.0"/>
                    <measurement group_id="O2" value="16.7" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change In Creatinine Blood Levels</title>
        <description>Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)</description>
        <time_frame>14 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>32ppm Oral Silver</title>
          </group>
        </group_list>
        <measure>
          <title>Change In Creatinine Blood Levels</title>
          <description>Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.92" spread="0.16"/>
                    <measurement group_id="O2" value="0.88" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change In Glucose Blood Levels</title>
        <description>Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)</description>
        <time_frame>14 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>32ppm Oral Silver</title>
          </group>
        </group_list>
        <measure>
          <title>Change In Glucose Blood Levels</title>
          <description>Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)</description>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.9" spread="10.7"/>
                    <measurement group_id="O2" value="83.5" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change In Alkaline Phosphatase Blood Level</title>
        <description>Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)</description>
        <time_frame>14 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>32ppm Oral Silver</title>
          </group>
        </group_list>
        <measure>
          <title>Change In Alkaline Phosphatase Blood Level</title>
          <description>Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)</description>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.0" spread="60.4"/>
                    <measurement group_id="O2" value="85.4" spread="48.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change In Aspartate Aminotransferase Blood Level</title>
        <description>Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)</description>
        <time_frame>14 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>32ppm Oral Silver</title>
          </group>
        </group_list>
        <measure>
          <title>Change In Aspartate Aminotransferase Blood Level</title>
          <description>Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)</description>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.1" spread="7.9"/>
                    <measurement group_id="O2" value="30.9" spread="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change In Alanine Aminotransferase Blood Level</title>
        <description>Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)</description>
        <time_frame>14 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>32ppm Oral Silver</title>
          </group>
        </group_list>
        <measure>
          <title>Change In Alanine Aminotransferase Blood Level</title>
          <description>Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)</description>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.1" spread="11.7"/>
                    <measurement group_id="O2" value="34.7" spread="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Total Protein Blood Levels</title>
        <description>Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)</description>
        <time_frame>14 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>32ppm Oral Silver</title>
          </group>
        </group_list>
        <measure>
          <title>Change in Total Protein Blood Levels</title>
          <description>Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)</description>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" spread="0.5"/>
                    <measurement group_id="O2" value="7.4" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change In Total Bilirubin Blood Levels</title>
        <description>Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)</description>
        <time_frame>14 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>32ppm Oral Silver</title>
          </group>
        </group_list>
        <measure>
          <title>Change In Total Bilirubin Blood Levels</title>
          <description>Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="0.3"/>
                    <measurement group_id="O2" value="0.8" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change In Albumin Blood Levels</title>
        <description>Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)</description>
        <time_frame>14 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>32ppm Oral Silver</title>
          </group>
        </group_list>
        <measure>
          <title>Change In Albumin Blood Levels</title>
          <description>Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)</description>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" spread="0.4"/>
                    <measurement group_id="O2" value="4.4" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change In Calcium Blood Level</title>
        <description>Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)</description>
        <time_frame>14 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>32ppm Oral Silver</title>
          </group>
        </group_list>
        <measure>
          <title>Change In Calcium Blood Level</title>
          <description>Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4" spread="0.4"/>
                    <measurement group_id="O2" value="9.4" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change In White Blood Count Blood Levels</title>
        <description>Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)</description>
        <time_frame>14 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>32ppm Oral Silver</title>
          </group>
        </group_list>
        <measure>
          <title>Change In White Blood Count Blood Levels</title>
          <description>Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)</description>
          <units>k/uL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.99" spread="1.24"/>
                    <measurement group_id="O2" value="5.92" spread="1.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change In Red Blood Count Blood Levels</title>
        <description>Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)</description>
        <time_frame>14 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>32ppm Oral Silver</title>
          </group>
        </group_list>
        <measure>
          <title>Change In Red Blood Count Blood Levels</title>
          <description>Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)</description>
          <units>M/uL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.07" spread="0.55"/>
                    <measurement group_id="O2" value="5.07" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change In Hemoglobin Blood Levels</title>
        <description>Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)</description>
        <time_frame>14 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>32ppm Oral Silver</title>
          </group>
        </group_list>
        <measure>
          <title>Change In Hemoglobin Blood Levels</title>
          <description>Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)</description>
          <units>gm/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.5" spread="1.4"/>
                    <measurement group_id="O2" value="15.5" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change In Hematocrit Blood Levels</title>
        <description>Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)</description>
        <time_frame>14 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>32ppm Oral Silver</title>
          </group>
        </group_list>
        <measure>
          <title>Change In Hematocrit Blood Levels</title>
          <description>Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)</description>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.0" spread="3.5"/>
                    <measurement group_id="O2" value="45.4" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change In Mean Corpuscular Volume Blood Levels</title>
        <description>Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)</description>
        <time_frame>14 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>32ppm Oral Silver</title>
          </group>
        </group_list>
        <measure>
          <title>Change In Mean Corpuscular Volume Blood Levels</title>
          <description>Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)</description>
          <units>fL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.1" spread="3.8"/>
                    <measurement group_id="O2" value="89.6" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change In Mean Corpuscular Hemoglobin Concentration Blood Levels</title>
        <description>Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)</description>
        <time_frame>14 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>32ppm Oral Silver</title>
          </group>
        </group_list>
        <measure>
          <title>Change In Mean Corpuscular Hemoglobin Concentration Blood Levels</title>
          <description>Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)</description>
          <units>gm/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.5" spread="1.0"/>
                    <measurement group_id="O2" value="34.2" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change In Platelet Blood Levels</title>
        <description>Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)</description>
        <time_frame>14 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>32ppm Oral Silver</title>
          </group>
        </group_list>
        <measure>
          <title>Change In Platelet Blood Levels</title>
          <description>Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)</description>
          <units>k/uL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="268" spread="59"/>
                    <measurement group_id="O2" value="253" spread="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change In Granulocytes Blood Levels</title>
        <description>Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)</description>
        <time_frame>14 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>32ppm Oral Silver</title>
          </group>
        </group_list>
        <measure>
          <title>Change In Granulocytes Blood Levels</title>
          <description>Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)</description>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.6" spread="6.9"/>
                    <measurement group_id="O2" value="53.4" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change In Lymphocytes Blood Levels</title>
        <description>Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)</description>
        <time_frame>14 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>32ppm Oral Silver</title>
          </group>
        </group_list>
        <measure>
          <title>Change In Lymphocytes Blood Levels</title>
          <description>Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)</description>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.7" spread="6.4"/>
                    <measurement group_id="O2" value="36.8" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change In Monocytes Blood Levels</title>
        <description>Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)</description>
        <time_frame>14 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>32ppm Oral Silver</title>
          </group>
        </group_list>
        <measure>
          <title>Change In Monocytes Blood Levels</title>
          <description>Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)</description>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4" spread="1.1"/>
                    <measurement group_id="O2" value="6.0" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change In Basophils Blood Levels</title>
        <description>Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)</description>
        <time_frame>14 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>32ppm Oral Silver</title>
          </group>
        </group_list>
        <measure>
          <title>Change In Basophils Blood Levels</title>
          <description>Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)</description>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="0.2"/>
                    <measurement group_id="O2" value="0.7" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change In Eosinophils Blood Levels</title>
        <description>Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)</description>
        <time_frame>14 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>32ppm Oral Silver</title>
          </group>
        </group_list>
        <measure>
          <title>Change In Eosinophils Blood Levels</title>
          <description>Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)</description>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="1.5"/>
                    <measurement group_id="O2" value="3.1" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cytochrome P450 Assay on Dextromethorphan in Participants</title>
        <description>Assessment Placebo (14 Days) and 32ppm Oral Silver (14 Days). Cytochrome P450 assay is used to determine the function of how Dextromethorphan metabolized. The value represents the peak absorption of the 450 enzyme when dextromethorphan is given during the Silver or Placebo Arm.</description>
        <time_frame>14 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>32ppm Oral Silver</title>
          </group>
        </group_list>
        <measure>
          <title>Cytochrome P450 Assay on Dextromethorphan in Participants</title>
          <description>Assessment Placebo (14 Days) and 32ppm Oral Silver (14 Days). Cytochrome P450 assay is used to determine the function of how Dextromethorphan metabolized. The value represents the peak absorption of the 450 enzyme when dextromethorphan is given during the Silver or Placebo Arm.</description>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.53" spread="5.04"/>
                    <measurement group_id="O2" value="2.18" spread="1.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cytochrome P450 Assay on Losartan in Participants</title>
        <description>Assessment Placebo (14 Days) and 32ppm Oral Silver (14 Days). Cytochrome P450 assay is used to determine the function of how Dextromethorphan metabolized. The value represents the peak absorption of the 450 enzyme when dextromethorphan is given during the Silver or Placebo Arm.</description>
        <time_frame>14 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>32ppm Oral Silver</title>
          </group>
        </group_list>
        <measure>
          <title>Cytochrome P450 Assay on Losartan in Participants</title>
          <description>Assessment Placebo (14 Days) and 32ppm Oral Silver (14 Days). Cytochrome P450 assay is used to determine the function of how Dextromethorphan metabolized. The value represents the peak absorption of the 450 enzyme when dextromethorphan is given during the Silver or Placebo Arm.</description>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.62" spread="0.42"/>
                    <measurement group_id="O2" value="1.76" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cytochrome P450 Assay on Caffeine in Participants</title>
        <description>Assessment Placebo (14 Days) and 32ppm Oral Silver (14 Days). Cytochrome P450 assay is used to determine the function of how Dextromethorphan metabolized. The value represents the peak absorption of the 450 enzyme when dextromethorphan is given during the Silver or Placebo Arm.</description>
        <time_frame>14 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>32ppm Oral Silver</title>
          </group>
        </group_list>
        <measure>
          <title>Cytochrome P450 Assay on Caffeine in Participants</title>
          <description>Assessment Placebo (14 Days) and 32ppm Oral Silver (14 Days). Cytochrome P450 assay is used to determine the function of how Dextromethorphan metabolized. The value represents the peak absorption of the 450 enzyme when dextromethorphan is given during the Silver or Placebo Arm.</description>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.34" spread="0.28"/>
                    <measurement group_id="O2" value="3.68" spread="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cytochrome P450 Assay on Omeprazole in Participants</title>
        <description>Assessment Placebo (14 Days) and 32ppm Oral Silver (14 Days). Cytochrome P450 assay is used to determine the function of how Dextromethorphan metabolized. The value represents the peak absorption of the 450 enzyme when dextromethorphan is given during the Silver or Placebo Arm.</description>
        <time_frame>14 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>32ppm Oral Silver</title>
          </group>
        </group_list>
        <measure>
          <title>Cytochrome P450 Assay on Omeprazole in Participants</title>
          <description>Assessment Placebo (14 Days) and 32ppm Oral Silver (14 Days). Cytochrome P450 assay is used to determine the function of how Dextromethorphan metabolized. The value represents the peak absorption of the 450 enzyme when dextromethorphan is given during the Silver or Placebo Arm.</description>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.19" spread="1.14"/>
                    <measurement group_id="O2" value="1.81" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cytochrome P450 Assay on Chlorozoxazone in Participants Dosed With Silver</title>
        <description>Assessment Placebo (14 Days) and 32ppm Oral Silver (14 Days). Cytochrome P450 assay is used to determine the function of how Dextromethorphan metabolized. The value represents the peak absorption of the 450 enzyme when dextromethorphan is given during the Silver or Placebo Arm.</description>
        <time_frame>14 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>32ppm Oral Silver</title>
          </group>
        </group_list>
        <measure>
          <title>Cytochrome P450 Assay on Chlorozoxazone in Participants Dosed With Silver</title>
          <description>Assessment Placebo (14 Days) and 32ppm Oral Silver (14 Days). Cytochrome P450 assay is used to determine the function of how Dextromethorphan metabolized. The value represents the peak absorption of the 450 enzyme when dextromethorphan is given during the Silver or Placebo Arm.</description>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2311" spread="494"/>
                    <measurement group_id="O2" value="1912" spread="334"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cytochrome P450 Assay on Midazolam in Participants</title>
        <description>Assessment Placebo (14 Days) and 32ppm Oral Silver (14 Days). Cytochrome P450 assay is used to determine the function of how Dextromethorphan metabolized. The value represents the peak absorption of the 450 enzyme when dextromethorphan is given during the Silver or Placebo Arm.</description>
        <time_frame>14 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>32ppm Oral Silver</title>
          </group>
        </group_list>
        <measure>
          <title>Cytochrome P450 Assay on Midazolam in Participants</title>
          <description>Assessment Placebo (14 Days) and 32ppm Oral Silver (14 Days). Cytochrome P450 assay is used to determine the function of how Dextromethorphan metabolized. The value represents the peak absorption of the 450 enzyme when dextromethorphan is given during the Silver or Placebo Arm.</description>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.62" spread="0.83"/>
                    <measurement group_id="O2" value="9.18" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Change in Systolic Blood Pressure Silver Participants</title>
        <description>Assessment only completed on the 32ppm Oral Silver part of the trail</description>
        <time_frame>Baseline and 14 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>32ppm Oral Silver</title>
          </group>
        </group_list>
        <measure>
          <title>Total Change in Systolic Blood Pressure Silver Participants</title>
          <description>Assessment only completed on the 32ppm Oral Silver part of the trail</description>
          <units>mmhg</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="-1.3" lower_limit="-3.0" upper_limit="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Change in Diastolic Blood Pressure Silver Participants</title>
        <description>Assessment only completed on the 32ppm Oral Silver part of the trail</description>
        <time_frame>Baseline and 14 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>32ppm Oral Silver</title>
          </group>
        </group_list>
        <measure>
          <title>Total Change in Diastolic Blood Pressure Silver Participants</title>
          <description>Assessment only completed on the 32ppm Oral Silver part of the trail</description>
          <units>mmhg</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="-0.7" lower_limit="-2.5" upper_limit="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Change in Heart Rate in Silver Participants</title>
        <description>Assessment only completed on the 32ppm Oral Silver part of the trail</description>
        <time_frame>Baseline and 14 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>32ppm Oral Silver</title>
          </group>
        </group_list>
        <measure>
          <title>Total Change in Heart Rate in Silver Participants</title>
          <description>Assessment only completed on the 32ppm Oral Silver part of the trail</description>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="-3.1" lower_limit="-6.4" upper_limit="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>ASAP 32 Ppm Solution Experimental</title>
        </group>
        <group group_id="E2">
          <title>Silver Biotics 32 Ppm Diluent</title>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <description>Pulmonary embolism at 12 days of placebo diluent.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Mark Munger</name_or_title>
      <organization>University of Utah</organization>
      <phone>801-581-6165</phone>
      <email>mmunger@hsc.utah.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

